In patients with endotoxic septic shock defined by high endotoxin activity and multiorgan failure, polymyxin B haemoadsorption was associated with a high probability of lower mortality at 28 days and 90 days.
The Lancet Respiratory Medicine published a clinical update in Critical Care on 23 Mar 2026. The item focuses on Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. Open the detail page to review the full original feed content.